Form 4: 4D Molecular Therapeutics Director John F. Milligan Granted Stock Options

John F. Milligan, a Director at 4D Molecular Therapeutics, Inc., was granted 33,750 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Summary

• John F. Milligan, a Director of 4D Molecular Therapeutics, Inc. (FDMT), was granted 33,750 stock options.
• The options have an exercise price of $4.15 per share.
• The grant date for these options was June 17, 2025.
• These options were automatically granted under the Company's non-employee director compensation program.
• The options will vest and become exercisable with respect to one-third (1/3) of the total shares on June 17, 2026, with the remaining shares vesting in equal monthly installments thereafter until fully vested on June 17, 2028.
• Full vesting will also occur upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan.
• The options expire on June 16, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns management interests with shareholders, generally viewed as a neutral to slightly positive development for corporate governance and long-term strategy.

Positives

• The grant of stock options to Director John F. Milligan aligns his interests with those of shareholders, incentivizing long-term performance.
• The options were granted as part of a pre-existing, automatically executed non-employee director compensation program, indicating a structured approach to executive incentives.

Negatives

• Potential for future dilution if the options are exercised, although this is a standard aspect of equity compensation.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The stock options are subject to a vesting schedule, with one-third vesting on June 17, 2026, and the remainder vesting monthly until fully vested on June 17, 2028, contingent on continued service. Full vesting will also occur upon a Change in Control.

Industry Context

Granting stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries to attract and retain experienced board members and align their financial interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options as part of a non-employee director compensation program is a standard and widely adopted practice across publicly traded companies, particularly within the biotech sector. While specific grant sizes and vesting schedules vary, the mechanism itself is consistent with industry benchmarks for incentivizing board members. No specific comparable companies or projects are mentioned in the filing to provide a direct numerical comparison.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director's interests with shareholder value creation.

Next Steps

• Continued service of John F. Milligan to 4D Molecular Therapeutics, Inc.
• Vesting of the granted stock options according to the specified schedule (June 17, 2026, and monthly thereafter until June 17, 2028).
• Potential exercise of stock options by John F. Milligan upon vesting.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, Stock Option, Director Compensation, SEC Form 4, Equity Grant, John F. Milligan, Insider Transaction, Biotechnology, Pharmaceuticals